Perioperative Management of Anticoagulant Therapy during Cutaneous Surgery: 2005 Survey of Mohs Surgeons
|
|
- Hugo Copeland
- 6 years ago
- Views:
Transcription
1 Perioperative Management of Anticoagulant Therapy during Cutaneous Surgery: 2005 Survey of Mohs Surgeons A. YASMINE KIRKORIAN, BA, BETTY L. MOORE,PHD, JODI SISKIND, BS, y AND ELLEN S. MARMUR,MD BACKGROUND The perioperative management of anticoagulation and antiplatelet therapy is a controversial topic in the field of dermatologic surgery. Dermasurgeons must weigh the risk of bleeding against the risk of thrombotic complications when deciding how to manage perioperative anticoagulation. OBJECTIVE Our aim is to present a summary of current practice in anticoagulation management perioperatively during cutaneous surgery. We compare our results to those found in a similar survey in METHODS AND MATERIALS A questionnaire surveying current practice in perioperative management of anticoagulant therapy was mailed to 720 dermasurgeons. RESULTS Thirty-eight percent of dermasurgeons responded to the questionnaire. Of the responding physicians, 87% discontinue prophylactic aspirin therapy, 37% discontinue medically necessary aspirin, 44% discontinue warfarin, 77% discontinue nonsteroidal anti-inflammatory drugs (NSAIDs), and 77% discontinue vitamin E therapy perioperatively at least some of the time. Although clopidogrel was not surveyed, 78 physicians included comments about the management of this agent. CONCLUSION Dermasurgeons were more likely to continue medically necessary aspirin and warfarin in 2005 compared to 2002, with the most dramatic shift evident in the management of warfarin. They were more likely to discontinue prophylactic aspirin, NSAIDs, and vitamin E. Surgeons were concerned about bleeding with the antiplatelet agent clopidogrel. More evidence-based medicine is necessary to set guidelines for the management of anticoagulation and antiplatelet therapy perioperatively. A. Yasmine Kirkorian, BA, Betty L. Moore, PhD, Jodi Siskind, BS, and Ellen S. Marmur, MD, have indicated no significant interest with commercial supporters. Many patients who present to the dermatologic surgeon for cutaneous surgery have other comorbidities for which they may be receiving anticoagulant or antiplatelet therapy. The perioperative management of such patients is a controversial topic in dermatologic surgery. Dermasurgeons must balance the risk of bleeding complications associated with continuing therapy versus the risk of thrombotic complications associated with cessation of anticoagulant therapy. Several prospective and retrospective studies have concluded that when bleeding complications occur, they are minor and rarely compromise wound healing or surgical outcome. 1 6 There have been numerous case reports of thrombotic events that were associated with the cessation of anticoagulation therapy There is no current standard of care and the management of anticoagulant and antiplatelet therapy varies widely among dermasurgeons and cutaneous surgeons from other specialties. The goal of our study is to describe the current state of perioperative management of anticoagulant and antiplatelet therapy in Mohs surgery. The role of the discussion will be to guide physicians in decision making regarding the perioperative management of these therapeutic agents and to suggest recommendations based on evidence in the literature. Materials and Methods A questionnaire surveying current practice in perioperative management of anticoagulant and antiplatelet therapy was mailed to 720 dermasurgeons, Department of Dermatology and y Department of Community and Preventive Medicine, Mount Sinai School of Medicine, New York, New York & 2007 by the American Society for Dermatologic Surgery, Inc. Published by Blackwell Publishing ISSN: Dermatol Surg 2007;33: DOI: /j x 1189
2 ANTICOAGULANT SURVEY members of the American College of Mohs Micrographic Surgery and Cutaneous Oncology (ACMMSCO). A mailing list of the complete membership was purchased from the ACMMSCO. Completion of the survey was voluntary and anonymous with no monetary compensation provided. The survey was reviewed by the Mount Sinai School of Medicine Institutional Review Board. The questions interrogated physicians on the following topics: (1) years in practice; (2) number of procedures performed yearly; (3) continuation or discontinuation of aspirin (prophylaxis), aspirin (medically necessary), warfarin, nonsteroidal antiinflammatory drugs (NSAIDs), and vitamin E; (4) time of discontinuation; (5) qualitative reasoning behind decision to continue or discontinue each anticoagulant or platelet inhibitor; and (6) the involvement of other physicians in determining how to manage the patient. The physicians were also asked to report on the number and type of thrombotic complications they had personally experienced in their own practices without any specific patient identifying information. The Wilcoxon rank sum was used to compare the median number of years in practice between surgeons who continue and discontinue each agent. The results were compared to those of a similar survey in Results A total of 271 of the 720 surveys were returned (response rate, 38%). Physicians were questioned about the number of specific procedures performed annually including excision, Mohs surgery, biopsy, blepharoplasty, and liposuction with the data displayed in Figure 1. Most responders performed between 101 and 500 or more than 500 excisions (88%), Mohs surgeries (98%), and biopsies (93%). In contrast, very few responders performed 100 to 500 blepharoplasties (1%) or liposuctions (2%) yearly with no responders performing more than 500 cases of either procedure. Most physicians (88%) contacted the patient s Frequency (%) 100% 90% 80% 70% 60% 50% 40% 30% 20% 10% 0% Excisions Mohs Biopsies Blepharoplasty Procedures Performed Yearly Liposuction Yearly Cases < > 500 Figure 1. The frequency of various surgical procedures performed by dermasurgeons according to the number of cases performed yearly. primary care physician or cardiologist to discuss anticoagulant therapy. Physicians were asked to indicate which factors apply to their decision to discontinue anticoagulation perioperatively. These factors include: (1) anticoagulation leads to excessive bleeding during surgery; (2) excessive time/effort is required to control bleeding during and after surgery; (3) consideration for the patient s perspective (e.g., bleeding during surgery is scary); and (4) compromise of the postsurgical outcome. Of the responding physicians, 62% indicated the first factor, 52% indicated the second, 17% indicated the third, and 67% indicated the fourth as relevant to their decision making. Physicians were also asked to report thrombotic events that occurred after surgery. The results are restricted to those events personally seen by the physician and do not include reports from colleagues or partners. The complications reported include 39 strokes, 19 myocardial infarctions, 17 cases of unstable angina, 25 transient ischemic attacks, 7 deep venous thromboses, 4 pulmonary emboli, and 15 deaths. A summary of the type and frequency of such events can be found in Table 1. A comparison of the management of each of the therapeutic agents is provided in Figure 2 and may be referredtowitheachsection.foreachtherapeutic agent, we compare the number of years in practice for physicians who continue and discontinue therapy DERMATOLOGIC SURGERY
3 KIRKORIAN ET AL TABLE 1. Thrombotic Events and Adverse Outcomes after Dermatologic Surgery Type of event Stroke (ischemic only, 39 not hemorrhagic) Myocardial infarction 19 Unstable angina 17 Transient ischemic attack 25 Deep venous thrombosis 7 Pulmonary embolus 4 Death 15 Physician response (n) Number of Physicians Number of Days Aspirin Prophalaxis Discontinued Perioperatively Figure 3. The number of physicians who discontinue prophylactic aspirin therapy perioperatively according to the number of days therapy is discontinued. Aspirin (Prophylaxis/Not Medically Necessary) Prophylactic aspirin is defined as that taken for pain relief or primary prophylaxis in the prevention of cardiovascular disease. Of the responding physicians, 49% always discontinue prophylactic aspirin perioperatively, 34% sometimes discontinue it, and 16% never discontinue it. The timing of discontinuation of prophylactic aspirin is summarized in Figure 3. The number of years in practice was not significantly different between the dermasurgeons who continue and discontinue prophylactic aspirin, medically necessary aspirin, warfarin, or NSAID therapy perioperatively. Aspirin (Medically Necessary) Medically necessary aspirin was defined as that prescribed to patients with a history of cardiovascular, thrombotic, or thromboembolic events. Of the responding physicians, 3% always discontinue medically necessary aspirin perioperatively, 34% sometimes discontinue it, and 63% never discontinue it. The timing of discontinuation of medically necessary aspirin is summarized in Figure 4. Warfarin (Coumadin) In contrast to aspirin, warfarin is prescribed and is defined as medically necessary. Of the responding physicians, 3% always discontinue warfarin perioperatively, 41% sometimes discontinue it, and 56% never discontinue it. The timing of discontinuation of warfarin is summarized in Figure 5. NSAIDs The therapeutic agents known as NSAIDs include ibuprofen, naproxen, and indomethacin. Of the Frequency (%) 70% 60% 50% 40% 30% 20% 10% 0% ASA (prescribed) Warfarin Plavix NSAIDs Vit.E ASA (prophylaxis) Anticoagulant and Antiplatelet Agents Always Sometimes Never Number of Physicians Number of Days Medically Necessary Aspirin Therapy Discontinued Perioperatively Figure 2. A comparison of management of various anticoagulant and antiplatelet agents according to frequency of discontinuation of each therapeutic agent. Figure 4. The number of physicians who discontinue medically necessary aspirin therapy perioperatively according to number of days the therapy is discontinued. 33:10:OCTOBER
4 ANTICOAGULANT SURVEY Number of Physicians Number of Days Warfarin Therapy Discontinued Perioperatively Figure 5. The number of physicians who discontinue warfarin therapy perioperatively according to the number of days the therapy is discontinued. from the literature in dermatologic surgery as well as in other fields. In deciding whether or not to continue anticoagulation, dermasurgeons balance the risk of bleeding complications with the risk of thrombotic complications. The weaknesses of the study include a low response rate, a lack of prospective data, and a lack of information on the occurrence of bleeding complications. To address the latter issue, we have concluded a survey to assess the level of bleeding complications experienced by Mohs surgeons. responding physicians, 32% always discontinue NSAIDs perioperatively, 45% sometimes discontinue them, and 24% never discontinue them. Vitamin E Of the responding physicians, 45% always discontinue vitamin E perioperatively, 32% sometimes discontinue it, and 23% never discontinue it. Physicians who have had more years in practice (median, 14 years; interquartile range, 6 17) are significantly more likely (p=.003) to continue vitamin E therapy perioperatively than physicians who have practiced for fewer years (median, 10 years; interquartile range, 4 15). Clopidogrel (Plavix) Although we did not directly ask about the antiplatelet agent clopidogrel, 78 physicians wrote this drug in the blank box for other anticoagulants. Of these responding physicians, 9% always discontinue clopidogrel perioperatively, 42% sometimes discontinue it, and 29% never discontinue it. The number of years in practice did not significantly affect the management of clopidogrel therapy. Discussion The purpose of the study is to describe the current state of management in Mohs surgery. A shift toward the maintenance of anticoagulation and antiplatelet therapy is supported by the evidence-based medicine Bleeding Complications A search of the dermatologic surgery literature revealed eight articles 1 8 that examine the risk of bleeding complications with perioperative anticoagulation or antiplatelet therapy and the effect of these complications postoperatively. The majority of the articles conclude that anticoagulant and antiplatelet therapy should be continued because the surgical outcome is similar between control and anticoagulated patients. Kargi and coworkers, 6 however, found that cutaneous surgery in patients who receive warfarin is associated with a risk of major complication (e.g., persistent bleeding, wound hematoma, loss of skin graft, wound infection), but concluded that minor surgery can be performed on patients taking warfarin as long as the surgeon is aware of the possibility of complications. In our survey, more than half (67%) of doctors who discontinued therapy said that the postsurgical outcome being compromised was at least one of the contributing factors to their decision. This opinion among Mohs surgeons is not supported by the literature as described above. This opinion may be due to several factors including the level of familiarity with the literature, belief that bleeding occurs despite the findings in the literature, and the potential that excessive bleeding, thus far undocumented, does occur in certain patients using anticoagulant or antiplatelet therapy. Although our survey did not specifically ask the respondents about 1192 DERMATOLOGIC SURGERY
5 KIRKORIAN ET AL their familiarity with the dermatologic literature, our findings demonstrate a shift in anticoagulant management of medically necessary aspirin and warfarin, which is consistent with the current recommendations. Although some physicians may believe that excessive bleeding occurs despite findings in the literature, West and colleagues 9 suggested that dermasurgeons cannot assess anticoagulation status of a patient by clinical inspection intraoperatively. Another possibility is that excessive perioperative bleeding does occur. Syed and coworkers 2 did note an increase in the risk of minor bleeding with warfarin but determined that this bleeding did not affect surgical outcome. The results of our forthcoming survey will describe the incidence of such complications. Thrombotic Complications Stroke, myocardial infarctions, and death are among the thrombotic complications that may result from the discontinuation of anticoagulation perioperatively during cutaneous surgery. Many authors in the dermatologic surgery literature have concluded that the potential for such complications, which are viewed as life-threatening, outweighs the minor risk of excessive bleeding. This point of view is supported by the literature in other fields including a survey 10 of 473 Canadian internists and cardiologists, which indicated that the risk of thromboembolism, but not the risk of bleeding, influenced the aggressiveness of anticoagulant management. It is possible that some perioperative thrombotic complications are the result of underlying disease in the coagulopathic patient independent of anticoagulation status. One study 11 of 6,108 patients with nonvalvular atrial fibrillation treated with or without warfarin defined a rate of 7.92 thromboembolic events per 100 person-years for patients treated with warfarin. Nevertheless, this same study concluded a risk of thromboembolic events per 100 person-years in patients not treated with warfarin. This rate was significantly higher (po.001) than in the untreated group indicating that, even within the context of the high-risk patient, patients who do not receive anticoagulation therapy are more likely to experience a thromboembolic event. Certain authors 12 have suggested that the connection between cessation of anticoagulation or antiplatelet therapy and the thrombotic event is tenuous and cannot be proven without a large-scale prospective trial. There is evidence for such a connection, however, as well as a proposed mechanism for the precipitation of thrombotic events after cessation of anticoagulation perioperatively Two large-scale retrospective analyses 14,15 in the cardiovascular literature describe an increased risk of thrombotic complications with cessation of anticoagulant or antiplatelet therapy. In a study of myocardial infarction after aspirin cessation, 13 the mechanism proposed for the provocation of a thrombotic event is the existence of a rebound state during the 2-week period of platelet recovery of function following cessation of aspirin therapy. The dermatologic surgery literature 12,17 19 also supports the correlation between cessation of anticoagulant and antiplatelet therapy and the incidence of thrombotic events. Kovich and Otley 19 calculated an incidence rate of 1 in 6,219 cases upon discontinuation of warfarin and 1 in 21,448 cases with discontinuation of aspirin therapy. They found that 24% of responding physicians had experienced a thrombotic event during their career. The authors concluded that half of all dermatologic surgeons are likely to experience a thrombotic complication. Our results support this assertion with 82 Mohs surgeons reporting 126 thrombotic events, including 39 strokes, 19 myocardial infarctions, 17 cases of unstable angina, 25 transient ischemic attacks, 7 deep venous thromboses, 4 pulmonary emboli, and 15 deaths. The physicians responding to our survey may have underreported the number of thrombotic complications. Patients with such complications may have presented directly to the emergency room and may 33:10:OCTOBER
6 ANTICOAGULANT SURVEY not have notified the reporting physician. Because the number of thrombotic events after discontinuation may be underreported, the continuation of anticoagulation perioperatively to prevent the chance of such complications may be important. Evidence from Other Fields The decision to maintain anticoagulant and antiplatelet therapy perioperatively is supported by the literature in several other fields, including ophthalmology, 20,21 dentistry, 22,23 and gastroenterology. 24 Of particular interest to dermasurgeons are the latest recommendations in plastic surgery. Many Mohs surgeons refer complicated repairs to their colleagues in other surgical fields, and it is important to be aware of the recommendations in other literature. Interestingly, a review article in the plastic surgery literature, published by Muskett and coworkers 25 in 2005, refers to the dermatologic surgery literature and concludes that for many minor or cutaneous procedures, anticoagulant and antiplatelet inhibitors do not need to be discontinued perioperatively. No current guidelines have been accepted by these surgical specialties, and this may pose a dilemma when referring between fields. Conclusion In 2002, Kovich and Otley 26 published an important survey that provided recommendations for the management of anticoagulation and antiplatelet therapy perioperatively in dermatologic surgery. In 2005, we compared our results to theirs, with their permission, to define the current state of practice and to demonstrate changes in the management of these therapeutic agents since The survey by Kovich and Otley found that 70% of Mohs surgeons continue medically necessary aspirin therapy but these physicians discontinue aspirin if not medically necessary (what we define as prophylactic aspirin). Furthermore, they found that 26% of Mohs surgeons always discontinue aspirin therapy regardless of medical indication. The 2005 survey results indicate a large divide between management of prophylactic aspirin, taken for primary prevention or pain relief, and medically necessary aspirin, prescribed to patients with a history of cardiovascular, thrombotic, or thromboembolic events. Although the majority (83%) of Mohs surgeons discontinue prophylactic aspirin at least some of the time, only 37% discontinue medically necessary aspirin in this manner with a minority (3%) who always discontinue aspirin therapy perioperatively. Overall results demonstrate that surgeons are more likely to continue aspirin therapy perioperatively. The 2002 study found that most (80%) Mohs surgeons discontinue warfarin therapy perioperatively at least some of the time. Our results indicate that less than half (44%) of surgeons discontinue such therapy today. This finding represents the most dramatic change in the perioperative management of anticoagulation, with a distinct shift toward the maintenance of warfarin therapy. The results regarding management of NSAIDs and vitamin E are less clear than those for aspirin and warfarin. This may reflect the fact that neither NSAIDs nor vitamin E were viewed as medically necessary agents. NSAIDs are often used as analgesics to combat arthritic joint pain. Seventy-seven percent of physicians discontinue these agents at least some of the time. Among these physicians, several commented that they preferred to discontinue NSAIDs and replace with acetaminophen or an opioid analgesic to maintain pain control in their patients. Vitamin E and other herbal supplements have been the subject of several articles in the recent dermatologic literature One such study by Collins and Dufresne 28 investigated the incidence of dietary supplement use in patients undergoing Mohs surgery. The authors found that 50% of patients admitted using some form of herbal supplementation when questioned specifically but only one third of these patients reported such usage on the initial questionnaire DERMATOLOGIC SURGERY
7 KIRKORIAN ET AL Vitamin E along with other herbal supplements such as garlic, ginkgo biloba, and ginseng cited by physicians in our survey are known to have antiplatelet properties. Vitamin E disrupts platelet aggregation and adhesionfparticularly when taken concomitantly with other antiplatelet agents such as aspirin. 29 We found that 32% of Mohs surgeons sometimes and 45% always discontinue vitamin E therapy perioperatively. In their comments regarding this agent, some physicians indicated intraoperative bleeding as the reason for discontinuation while others described vitamin E as having no clinical benefit. Despite numerous small trials and case reports, there is still a lack of evidence for the use of vitamin E in the treatment of dermatologic disorders. 27 Numerous large-scale, randomized trials have proven the benefit of clopidogrel (Plavix), an antiplatelet agent, in reducing the risk of thrombotic events Although we did not ask about clopidogrel specifically in our survey, 78 physicians included comments about the management of this agent indicating its importance in dermatologic surgery. Mohs surgeons are less likely to always discontinue clopidogrel (9%) than they are to discontinue prophylactic aspirin (49%), NSAIDs (32%), or vitamin E (45%). Several physicians mentioned that the level of perioperative bleeding in patients treated with clopidogrel is equal to or more significant than that seen with patients treated with aspirin. This assertion is supported by the literature in which the combination of aspirin and clopidogrel has been found to lead to excessive bleeding, outweighing the benefit of reduction of risk of thrombosis. 33 The management of antiplatelet agents is further complicated by the widespread use of drug-eluting coronary stents. Patients with such stents must maintain long-term therapy with aspirin and clopidogrel. The risk of late stent thrombosis appears to be greater in these patients in comparison to patients who were treated with nondrug eluting (e.g., baremetal) stents. 34 This represents a group of patients for whom the continuation of antiplatelet therapy is essential. In contrast, the recent CHARISMA trial 35 suggests that patients who are at a lower risk for coronary artery disease, and who have not been treated with a coronary stent, may not benefit from clopidogrel altogether; in such patients, cessation of antiplatelet therapy is likely to be beneficial. Given the rapid evolution of this field, it may be prudent for dermasurgeons to consult with the patient s cardiologist, especially in those cases where the patient may have received a stent. Recommendations for the Management of Anticoagulant and Antiplatelet Agents Perioperatively in Cutaneous Surgery The continuation of medically necessary anticoagulant and antiplatelet therapy is becoming the standard of care in the field of Mohs surgery. In most patients, Mohs surgeons should continue medically necessary anticoagulant and antiplatelet therapy perioperatively. This conclusion is supported by this survey and the literature. Exceptions will occur and all decisions are ultimately up to the discretion of the operating physicians. Eventually, evidence-based medicine may prove that it is safe to discontinue anticoagulation in the majority of low-risk cardiac patients. The literature and the number of adverse events described in this study (126), however, support the continuation of medically necessary anticoagulation. Dermasurgeons should document a current international normalized ratio (INR) value in patients treated with warfarin. There is no official recommendation for an acceptable range of perioperative INR values in the literature, but many dermasurgeons request the INR be between 2.0 and 3.0 at the time of cutaneous surgery unless otherwise specified by the prescribing physician. Dermasurgeons should use meticulous technique when performing surgery on the anticoagulated patient to minimize the risk of bleeding. There is no evidence-based medicine for the management of non medically necessary anticoagulants, 33:10:OCTOBER
8 ANTICOAGULANT SURVEY including prophylactic aspirin, NSAIDs, vitamin E, and other herbal supplements. The management of these agents should be at the physician s discretion. Further evidence-based medicine is necessary to set more strict guidelines for the perioperative management of anticoagulation and antiplatelet therapy. These guidelines are important to set safe standards throughout the dermatologic surgery community with regard to medically necessary anticoagulant and antiplatelet therapy. References 1. Alcalay J, Alkalay R. Controversies in perioperative management of blood thinners in dermatologic surgery: continue or discontinue? Dermatol Surg 2004;30: Syed S, Adams BB, Liao W, et al. A prospective assessment of bleeding and international normalized ratio in warfarin-anticoagulated patients having cutaneous surgery. J Am Acad Dermatol 2004;51: Shalom A, Wong L. Outcome of aspirin use during excision of cutaneous lesions. Ann Plast Surg 2003;50: Ah-Weng A, Natarajan S, Velangi S, Langtry JA. Preoperative monitoring of warfarin in cutaneous surgery. Br J Dermatol 2003;149: Stables G, Lawrence CM. Management of patients taking anticoagulant, aspirin, non-steroidal anti-inflammatory and other anti-platelet drugs undergoing dermatological surgery. Clin Exp Dermatol 2002;27: Kargi E, Babuccu O, Hosnuter M, et al. Complications of minor cutaneous surgery in patients under anticoagulant treatment. Aesthetic Plast Surg 2002;26: Alcalay J. Cutaneous surgery in patients receiving warfarin therapy. Dermatol Surg 2001;27: Bartlett GR. Does aspirin affect the outcome of minor cutaneous surgery? Br J Plast Surg 1999;52: West SW, Otley CC, Nguyen TH, et al. Cutaneous surgeons cannot predict blood-thinner status by intraoperative visual inspection. Plast Reconstr Surg 2002;110: Douketis JD, Crowther MA, Cherian SS, Kearon CB. Physician preferences for perioperative anticoagulation in patients with a mechanical heart valve who are undergoing elective noncardiac surgery. Chest 1999;116: Currie CJ, Jones M, Goodfellow J, et al. Evaluation of survival and ischaemic event rates in patients with non-valvar atrial fibrillation in the general population when treated and untreated with warfarin. Heart 2006;92: Kimyai-Asadi A, Jih MH, Goldberg LH. Perioperative primary stroke: is aspirin cessation to blame? Dermatol Surg 2004;30: Collet JP, Himbert D, Steg PG. Myocardial infarction after aspirin cessation in stable coronary artery disease patients. Int J Cardiol 2000;76: Hackam DG, Kopp A, Redelmeier DA. Prognostic implications of warfarin cessation after major trauma: a population-based cohort analysis. Circulation 2005;111: Fischer LM, Schlienger RG, Matter CM, et al. Discontinuation of nonsteroidal anti-inflammatory drug therapy and risk of acute myocardial infarction. Arch Intern Med 2004;164: Dunn AS, Turpie AG. Perioperative management of patients receiving oral anticoagulants: a systematic review. Arch Intern Med 2002;163: Alam M, Goldberg LH. Serious adverse vascular events associated with perioperative interruption of antiplatelet and anticoagulant therapy. Dermatol Surg 2002;28: Schanbacher CF, Bennett RG. Postoperative stroke after stopping warfarin for cutaneous surgery. Dermatol Surg 2002;26: Kovich O, Otley CC. Thrombotic complications related to discontinuation of warfarin and aspirin therapy perioperatively for cutaneous operation. J Am Acad Dermatol 2003;48: Ong-Tone L, Paluck EC, Hart-Mitchell RD. Perioperative use of warfarin and aspirin in cataract surgery by Canadian Society of Cataract and Refractive Surgery members: Survey. J Cataract Refract Surg 2005;31: Custer PL, Trinkhaus KM. Hemorrhagic complications of oculoplastic surgery. Ophthal Plast Reconstr Surg 2002;18: Malden N. Dental procedures can be undertaken without alteration of oral anticoagulant regimen. Evid Based Dent 2005;6: Jeske AH, Suchko GD. Lack of a scientific basis for routine discontinuation of oral anticoagulation therapy before dental treatment. J Am Dent Assoc 2003;134: Makar GA, Ginsberg GG. Therapy insight: approaching endoscopy in anticoagulated patients. Nat Clin Pract Gastroenterol Hepatol 2006;3: Muskett A, Barber WH, Lineaweaver WC. The plastic surgeon s guide to drugs affecting hemostasis. Ann Plast Surg 2005;54: Kovich O, Otley CC. Perioperative management of anticoagulants and platelet inhibitors for cutaneous surgery: a survey of current practice. Dermatol Surg 2002;28: Thiele JJ, Hsieu SN, Ekanayake-Mudiyanselage S. Vitamin E: critical review of its current use in cosmetic and clinical dermatology. Dermatol Surg 2005;31: Collins SC, Dufresne RG. Dietary supplements in the setting of Mohs surgery. Dermatol Surg 2002;28: Dinehart SM, Henry L. Dietary supplements: altered coagulation and effects on bruising. Dermatol Surg 2005;31: A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee. Lancet 1996;348: Ringleb PA, Bhatt DL, Hirsch AT, et al. Benefit of clopidogrel over aspirin is amplified in patients with a history of ischemic events. Stroke 2004;35: DERMATOLOGIC SURGERY
9 KIRKORIAN ET AL 32. Bhatt DL, Marso SP, Hisrch AT, et al. Amplified benefit of clopidogrel versus aspirin in patients with diabetes mellitus. Am J Cardiol 2002;90: Bezerra DC, Bogousslavsky J. Antiplatelets in stroke prevention: the MATCH trial. Cerebrovasc Dis 2005;20: McFadden EP, Stabile E, Regar E, et al. Late thrombosis in drugeluting coronary stents after discontinuation of antiplatelet therapy. Lancet 2004;364: Bhatt DL, Topol EJ. Clopidogrel added to aspirin versus aspirin alone in secondary prevention and high-risk primary prevention: Rationale and design of the clopidogrel for high atherothrombotic risk and ischemic stabilization, management, and avoidance (CHARISMA) trial. Am Heart J 2004;148: Address correspondence and reprint requests to: Ellen S. Marmur, MD, Chief, Division of Dermatology & Cosmetic Surgery, Mount Sinai School of Medicine, 5 East 98th Street, 5th floor, Box 1048, New York, NY , or ellen.marmur@mssm.edu 33:10:OCTOBER
Anticoagulant Complications in Facial Plastic and Reconstructive Surgery
Research Original Investigation Anticoagulant Complications in Facial Plastic and Reconstructive Surgery Casey T. Kraft, BS; Emily Bellile, MS; Shan R. Baker, MD; Jennifer C. Kim, MD; Jeffrey S. Moyer,
More informationAnticoagulants and Head Injuries. Asaad Shujaa,MD,FRCPC,FAAEM Assistant Professor,weill Corneal Medicne Senior Consultant,HMC Qatar
Anticoagulants and Head Injuries Asaad Shujaa,MD,FRCPC,FAAEM Assistant Professor,weill Corneal Medicne Senior Consultant,HMC Qatar Common Anticoagulants and Indications Coumadin (warfarin) indicated for
More informationPreoperative Management of Patients Receiving Antithrombotics
Preoperative Management of Patients Receiving Antithrombotics Bleeding complications remain an important concern for most surgical procedures. Attempts to minimize the risk of these complications by removing
More informationDental Management Considerations for Patients on Antithrombotic Therapy
Dental Management Considerations for Patients on Antithrombotic Therapy Warfarin and Antiplatelet Joel J. Napeñas DDS FDSRCS(Ed) Program Director General Practice Residency Program Department of Oral Medicine
More informationSlide 1: Perioperative Management of Anticoagulation
Perioperative Management of Anticoagulation by Steven L. Cohn, MD, FACP Director, Medical Consultation Service, Kings County Hospital Center, Clinical Professor of Medicine, SUNY Downstate, Brooklyn, NY
More informationAnticoagulation Management Around Endoscopy: GI Perspective. Nathan Landesman, DO FACOI Flint Gastroenterology Associates October 11, 2017
Anticoagulation Management Around Endoscopy: GI Perspective Nathan Landesman, DO FACOI Flint Gastroenterology Associates October 11, 2017 EDUCATIONAL OBJECTIVES Understand risks of holding anticoagulation
More information2010, Metzler Helfried
Perioperative Strategies in Patients on Dual Antiplatelet Drug Therapy: Noncardiac Surgery H. Metzler Department of Anaesthesiology and Intensive Care Medicine Medical University of Graz, Austria What
More informationClopidogrel has been evaluated in clinical trials that included cardiovascular patients
REVIEW ARTICLE Comparative Benefits of Clopidogrel and Aspirin in High-Risk Patient Populations Lessons From the CAPRIE and CURE Studies Jack Hirsh, CM, MD, FRCPC, FRACP, FRSC, DSc; Deepak L. Bhatt, MD,
More informationANTITHROMBOTIC THERAPY 2010 Antitrombotik tedavi alan hastalarda operasyon hazırlığı
ANTITHROMBOTIC THERAPY 2010 Antitrombotik tedavi alan hastalarda operasyon hazırlığı Dr. Sabri DEMİRCAN Ondokuz Mayıs Üniversitesi Tıp Fakültesi Kardiyoloji ABD, Samsun Copyright 2001 Harcourt Canada Ltd.
More informationProstate Biopsy Alerts
Prostate Biopsy Alerts Saskatchewan Prostate Assessment Pathway Guidelines for the Primary Care Provider for Patient Preparation and the Management of Medications and Complications September 2016 Table
More informationCASE IN... Anticoagulation: When to Start,When to Stop. The management of patients who require an. Meet Tracey. Anticoagulation
Anticoagulation: When to Start,When to Stop Ebtisam Bakhsh, MD; and James D. Douketis, MD, FRCPC Presented at McMaster University s Thrombosis and Hematology Update, October 2006. CASE IN... Anticoagulation
More informationImportant Information about Mohs Micrographic Surgery
Important Information about Mohs Micrographic Surgery Highly effective skin cancer treatment What is Mohs micrographic surgery? Mohs micrographic surgery is a highly effective technique for removing skin
More informationHEART OF THE MATTER: cardiac issues in safe endoscopy & sedation
HEART OF THE MATTER: cardiac issues in safe endoscopy & sedation YUVAL KONSTANTINO M.D. CARDIOLOGY DEPARTMENT, ELECTROPHYSIOLOGY UNIT, SOROKA MEDICAL CENTER, BEN-GURION UNIVERSITY OUTLINE 1 2 3 Anticoagulation
More informationAnti-platelet therapies and dual inhibition in practice
Anti-platelet therapies and dual inhibition in practice Therapeutics; Sept. 25 th 2007 Craig Williams, Pharm.D. Associate Professor of Pharmacy Objectives 1. Understand the pharmacology of thienopyridine
More informationComplicated issues in GI bleeding for internists? Nonthalee Pausawasdi, M.D. Faculty of Medicine Siriraj Hospital
Complicated issues in GI bleeding for internists? Nonthalee Pausawasdi, M.D. Faculty of Medicine Siriraj Hospital Complicated issues in GI bleeding; Survey results from internists Optimal resuscitation
More information- May Help Increase Appropriate Early Use in Acute Coronary Syndrome Patients -
MEDIA INVESTORS Ken Dominski John Elicker Bristol-Myers Squibb Bristol-Myers Squibb 609-252-5251 212-546-3775 ken.dominski@bms.com john.elicker@bms.com Amy Ba Felix Lauscher sanofi-aventis sanofi-aventis
More informationClinical Practice Committee Anticoagulation Bridging Document
Original: 10/23/06 Last Updated: 10/30/07 Clinical Practice Committee Do patients on long term oral anticoagulant therapy who require short term interruption of warfarin for an elective invasive procedure
More informationASA PLAVIX AND PREOPERATIVE OPTIMIZATION. John Hann, MD
ASA PLAVIX AND PREOPERATIVE OPTIMIZATION John Hann, MD QUESTIONS: WHICH ANTI-PLATELETS DO YOU STOP AND WHEN? 1. 65 yo M with history of stroke on ASA PreOp eval for cataracts surgery 2. 65 yo M with RCRI
More informationWARFARIN: PERI OPERATIVE MANAGEMENT
WARFARIN: PERI OPERATIVE MANAGEMENT OBJECTIVE: To provide an approach to the perioperative management of warfarin treated patients who require an elective or urgent surgery/procedure. To provide an approach
More informationTo provide information on the use of acetyl salicylic acid in the treatment and prevention of vascular events.
ACETYL SALICYLIC ACID TARGET AUDIENCE: All Canadian health care professionals. OBJECTIVE: To provide information on the use of acetyl salicylic acid in the treatment and prevention of vascular events.
More informationAmerican College of Cardiology 66th Annual Scientific Session (ACC.17):
News Release Not intended for U.S. and UK Media Bayer AG Communications and Public Affairs 51368 Leverkusen Germany Tel. +49 214 30-0 www.news.bayer.com American College of Cardiology 66th Annual Scientific
More informationHow Long Patietns Will Be on Dual Antiplatelet Therapy?
How Long Patietns Will Be on Dual Antiplatelet Therapy? Ron Waksman,, MD, FACC Professor of Medicine (Cardiology) Georgetown University Associate Director, Division of Cardiology, Washington Hospital Center
More informationManagement of Anticoagulation during Device Implants; Coumadin to Novel Agents
Management of Anticoagulation during Device Implants; Coumadin to Novel Agents DR D Birnie Invited Faculty Core Curriculum Heart Rhythm Society May 8 th 2014 Disclosures Boehringer Ingleheim Research Support
More informationMayo Clin Proc, November 2003, Vol 78 Perioperative Anticoagulant Therapy 1393 patients such that life-threatening complications would be a major risk
1392 Review Continuation of Medically Necessary Aspirin and Warfarin During Cutaneous Surgery CLARK C. OTLEY, MD Excisional cutaneous surgery is performed commonly in patients who take medically necessary
More informationOUTPATIENT ANTITHROMBOTIC MANAGEMENT POST NON-ST ELEVATION ACUTE CORONARY SYNDROME. TARGET AUDIENCE: All Canadian health care professionals.
OUTPATIENT ANTITHROMBOTIC MANAGEMENT POST NON-ST ELEVATION ACUTE CORONARY SYNDROME TARGET AUDIENCE: All Canadian health care professionals. OBJECTIVE: To review the use of antiplatelet agents and oral
More informationWARFARIN: PERI-OPERATIVE MANAGEMENT
WARFARIN: PERI-OPERATIVE MANAGEMENT OBJECTIVE: To provide an approach to the perioperative management of warfarin-treated patients who require an elective or urgent surgery/procedure. To provide an approach
More informationDaiichi Sankyo and Lilly Receive U.S. FDA Approval for Effient
For Immediate Release Company name: DAIICHI SANKYO COMPANY, LIMITED Representative: Takashi Shoda, President and Representative Director (Code no.: 4568, First Section, Tokyo, Osaka and Nagoya Stock Exchanges)
More informationOral anti-thrombotic therapy-management in patients requiring endoscopy
Oral anti-thrombotic therapy-management in patients requiring endoscopy Management of anti-thrombotic therapy in patients requiring endoscopy This guideline suggests appropriate management of patients
More informationThe Challenge. Warfarin or Novel Oral Anti-Coagulants in the PCI patient? Anticoagulation/Stroke
Anticoagulation/Stroke Warfarin v new oral anticoagulants post PCI Warfarin or Novel Oral Anti-Coagulants in the PCI patient? Gerry Devlin Chairs: Phillip Matsis & Tony Scott Gerry Devlin Honorary Associate
More informationResults from RE-LY and RELY-ABLE
Results from RE-LY and RELY-ABLE Assessment of the safety and efficacy of dabigatran etexilate (Pradaxa ) in longterm stroke prevention EXECUTIVE SUMMARY Dabigatran etexilate (Pradaxa ) has shown a consistent
More informationAntiplatelet and Anti-Thrombotic Therapy. Ivan Anderson, MD RIHVH Cardiology
Antiplatelet and Anti-Thrombotic Therapy Ivan Anderson, MD RIHVH Cardiology Outline Anti-thrombotic therapy Risk stratification of stroke with atrial fibrillation DVT and PE treatment Pharmacology Anti-platelet
More informationAPPENDIX A NORTH AMERICAN SYMPTOMATIC CAROTID ENDARTERECTOMY TRIAL
APPENDIX A Primary Findings From Selected Recent National Institute of Neurological Disorders and Stroke-Sponsored Clinical Trials That Have shaped Modern Stroke Prevention Philip B. Gorelick 178 NORTH
More informationClinical Practice Guideline for Anticoagulation Management
Clinical Practice Guideline for Anticoagulation Management This guideline is to inform practitioners of the Standard of Care for providing safe and effective anticoagulation management for ambulatory patients.
More information325 mg aspirin and plavix
325 mg aspirin and plavix 12-3-2006 Background Dual antiplatelet therapy with clopidogrel plus low-dose aspirin has not been studied in a broad population of patients at high risk for. Compare Aspirin
More informationPatients on anticoagulant or antiplatelet therapy undergoing elective endoscopic procedures
This is an official Northern Trust policy and should not be edited in any way Patients on anticoagulant or antiplatelet therapy undergoing elective endoscopic procedures Reference Number: NHSCT/11/454
More informationDisclosures. Theodore A. Bass MD, FSCAI. The following relationships exist related to this presentation. None
SCAI Fellows Course December 10, 2013 Disclosures Theodore A. Bass MD, FSCAI The following relationships exist related to this presentation None Current Controversies on DAPT in PCI Which drug? When to
More informationDECLARATION OF CONFLICT OF INTEREST. Lecture fees: AstraZeneca, Ely Lilly, Merck.
DECLARATION OF CONFLICT OF INTEREST Lecture fees: AstraZeneca, Ely Lilly, Merck. Risk of stopping dual therapy. S D Kristensen, FESC Aarhus Denmark Acute coronary syndrome: coronary thrombus Platelets
More informationBridging anticoagulation definition
Bridging anticoagulation definition Giving a short-acting anticoagulant, consisting of sc LMWH or ev UFH for 10 to 12 day period during interruption of VKA therapy when the INR is not within therapeutic
More informationDr Julia Hopyan Stroke Neurologist Sunnybrook Health Sciences Centre
Dr Julia Hopyan Stroke Neurologist Sunnybrook Health Sciences Centre Objectives To learn what s new in stroke care 2010-11 1) Acute stroke management Carotid artery stenting versus surgery for symptomatic
More informationApixaban for stroke prevention in atrial fibrillation. August 2010
Apixaban for stroke prevention in atrial fibrillation August 2010 This technology summary is based on information available at the time of research and a limited literature search. It is not intended to
More informationAlberta Colorectal Cancer Screening Program (ACRCSP) Antithrombotic Management
Alberta Colorectal Cancer Screening Program (ACRCSP) Antithrombotic Management Assessment Tools and Suggested Management for the Patient on Antithrombotics Undergoing a Screening-Related Colonoscopy Version
More informationGRAND ROUNDS - DILEMMAS IN ANTICOAGULATION AND ANTIPLATELET THERAPY. Nick Collins February 2017
GRAND ROUNDS - DILEMMAS IN ANTICOAGULATION AND ANTIPLATELET THERAPY Nick Collins February 2017 DISCLOSURES Before I commence Acknowledge.. Interventional Cardiologist Perception evolved. Interventional
More informationASPIRIN AND VASCULAR DISEASE
ASPIRIN AND VASCULAR DISEASE SUMMARY Aspirin is an effective antiplatelet agent for patients with cardiovascular and cerebrovascular disease. Incidence of adverse effects and drug interactions increases
More informationManagement of Patients with Atrial Fibrillation Undergoing Coronary Artery Stenting 경북대의전원내과조용근
Management of Patients with Atrial Fibrillation Undergoing Coronary Artery Stenting 경북대의전원내과조용근 Case (2011, 5) 74-years old gentleman Exertional chest pain Warfarin with good INR control Ex-smoker, social(?)
More informationBayer s rivaroxaban submitted to U.S. FDA for approval in patients with coronary and/or peripheral artery disease
Investor News Not intended for U.S. and UK Media Bayer AG Investor Relations 51368 Leverkusen Germany www.investor.bayer.com Bayer s rivaroxaban submitted to U.S. FDA for approval in patients with coronary
More information3/23/2017. Angelika Cyganska, PharmD Austin T. Wilson, MS, PharmD Candidate Europace Oct;14(10): Epub 2012 Aug 24.
Angelika Cyganska, PharmD Austin T. Wilson, MS, PharmD Candidate 2017 Explain the efficacy and safety of triple therapy, in regards to thromboembolic and bleeding risk Summarize the guideline recommendations
More informationBalancing Efficacy and Safety of P2Y12 Inhibitors for ACS Patients
SYP.CLO-A.16.07.01 Balancing Efficacy and Safety of P2Y12 Inhibitors for ACS Patients dr. Hariadi Hariawan, Sp.PD, Sp.JP (K) TOPICS Efficacy Safety Consideration from Currently Available Antiplatelet Agents
More informationAngelika Cyganska, PharmD Austin T. Wilson, MS, PharmD Candidate 2017
Angelika Cyganska, PharmD Austin T. Wilson, MS, PharmD Candidate 2017 Explain the efficacy and safety of triple therapy, in regards to thromboembolic and bleeding risk Summarize the guideline recommendations
More informationPerioperative Management of Anticoagulation
Perioperative Management of Anticoagulation Presented By: Nibal R. Chamoun, PharmD, BCPS Clinical Assistant Professor, Clinical Coordinator Lebanese American University, School of Pharmacy Presented at:
More informationNew Study Presented at American Heart Association (AHA) Scientific Sessions 2016:
Investor News Not intended for U.S. and UK Media Bayer AG Investor Relations 51368 Leverkusen Germany www.investor.bayer.com New Study Presented at American Heart Association (AHA) Scientific Sessions
More informationAspirin at the Intersection of Antiplatelet and Anticoagulant Therapy An Act of Commission?
Aspirin at the Intersection of Antiplatelet and Anticoagulant Therapy An Act of Commission? Ty J. Gluckman, MD, FACC, FAHA Medical Director, Center for Cardiovascular Analytics, Research and Data Science
More informationAspirin to Prevent Heart Attack and Stroke: What s the Right Dose?
The American Journal of Medicine (2006) 119, 198-202 REVIEW Aspirin to Prevent Heart Attack and Stroke: What s the Right Dose? James E. Dalen, MD, MPH Professor Emeritus, University of Arizona, Tucson
More informationMANAGEMENT OF OVERANTICOAGULATION AND PREOPERATIVE MANAGEMENT OF WARFARIN DOSE 1. GUIDELINES FOR THE MANAGEMENT OF AN ELEVATED INR
MANAGEMENT OF OVERANTICOAGULATION AND PREOPERATIVE MANAGEMENT OF WARFARIN DOSE 1. GUIDELINES FOR THE MANAGEMENT OF AN ELEVATED INR 1.1 Time to lower INR Prothrombinex-VF - 15 minutes Fresh Frozen Plasma
More informationNEW/NOVEL ORAL ANTICOAGULANTS (NOACS): COMPARISON AND FREQUENTLY ASKED QUESTIONS
NEW/NOVEL ORAL ANTICOAGULANTS (NOACS): COMPARISON AND FREQUENTLY ASKED QUESTIONS OBJECTIVES: To provide a comparison of the new/novel oral anticoagulants (NOACs) currently available in Canada. To address
More informationNeuroPI Case Study: Anticoagulant Therapy
Case: An 82-year-old man presents to the hospital following a transient episode of left visual field changes. His symptoms lasted 20 minutes and resolved spontaneously. He has a normal neurological examination
More informationUsing DOACs in CAD Patients in Sinus Ryhthm Results of the ATLAS ACS 2, COMPASS and COMMANDER-HF Trials
Using DOACs in CAD Patients in Sinus Ryhthm Results of the ATLAS ACS 2, COMPASS and COMMANDER-HF Trials 19 th Annual San Diego Heart Failure Symposium for Primary Care Physicians January 11-12, 2019 La
More informationCADTH Therapeutic Review
Canadian Agency for Drugs and Technologies in Health Agence canadienne des médicaments et des technologies de la santé CADTH Therapeutic Review August 2012 Volume 1, Issue 1A Antithrombotic Therapy for
More informationBayer s Rivaroxaban Demonstrated Superior Protection Against Recurrent Venous Thromboembolism Compared with Aspirin in EINSTEIN CHOICE Study
News Release Not intended for U.S. and UK Media Bayer AG Communications and Public Affairs 51368 Leverkusen Germany Tel. +49 214 30-0 www.news.bayer.com New Late-Breaking Study Data Presented at ACC.17:
More informationFølgende dias er fremlagt ved DCS / DTS Fællesmøde 13. januar 2011 og alle rettigheder tilhører foredragsholderen. Gengivelse må kun foretages ved
. Følgende dias er fremlagt ved DCS / DTS Fællesmøde 13. januar 2011 og alle rettigheder tilhører foredragsholderen. Gengivelse må kun foretages ved tilladelse Antithrombotic therapy in Atrial Fibrillation
More informationBleeding Management with Extractions
Bleeding Management with Extractions WHAT YOU WILL LEARN IN THIS SEGMENT: What is INR? Do you stop Coumadin before extractions or not? If not, how many teeth can be removed per appointment? Which local
More informationClinical and Economic Value of Rivaroxaban in Coronary Artery Disease
CHRISTOPHER B. GRANGER, MD Professor of Medicine Division of Cardiology, Department of Medicine; Director, Cardiac Care Unit Duke University Medical Center, Durham, NC Clinical and Economic Value of Rivaroxaban
More information8/28/2018. Pre-op Evaluation for non cardiac surgery. A quick review from 2007!! Disclosures. John Steuter, MD. None
Pre-op Evaluation for non cardiac surgery John Steuter, MD Disclosures None A quick review from 2007!! Fliesheret al, ACC/AHA 2007 Guidelines on Perioperative Cardiovascular Evaluation and are for Noncardiac
More informationCOAGULATION, BLEEDING, AND TRANSFUSION IN URGENT AND EMERGENCY CORONARY SURGERY
COAGULATION, BLEEDING, AND TRANSFUSION IN URGENT AND EMERGENCY CORONARY SURGERY VALTER CASATI, M.D. DIVISION OF CARDIOVASCULAR ANESTHESIA AND INTENSIVE CARE CLINICA S. GAUDENZIO NOVARA (ITALY) ANTIPLATELET
More informationScope of the Problem: DAPT and Triple Therapy after Stenting
Scope of the Problem: DAPT and Triple Therapy after Stenting Kurt Huber, MD, FESC, FACC 3 rd Medical Department Cardiology & Emergency Medicine Wilhelminenhospital Vienna, Austria Session, August 30, 2010,
More informationAnticoagulation in dental surgery: Is it rude to interrupt?
COMMENTARY MICHAEL J. WAHL, DDS Department of Oral and Maxillofacial Surgery and Hospital Dentistry, Christiana Care Health System, Wilmington, DE; Wahl Family Dentistry, Wilmington, DE Anticoagulation
More informationNOACS/DOACS*: PERI-OPERATIVE MANAGEMENT
NOACS/DOACS*: PERI-OPERATIVE MANAGEMENT OBJECTIVE: To provide guidance for the peri-operative management of patients who are receiving a newer direct oral anticoagulant (DOAC) and require an elective surgery/procedure.
More informationUpdate in Perioperative Anticoagulation and Antiplatelet management
Update in Perioperative Anticoagulation and Antiplatelet management Grand Rounds October 31, 2014 Brooke Hall, MD Steve Kornfeld, MD Bruce McLellan, MD Nothing to disclose Objectives Describe the updates
More informationChallenging Anticoagulation Case Studies. Earl J. Hope, M.D. Tower Health Cardiology
Challenging Anticoagulation Case Studies Earl J. Hope, M.D. Tower Health Cardiology Financial Disclosures Nothing to disclose Objectives: 1. Understand indications for heparin bridging. 2. Recognize the
More informationOptimal Duration and Dose of Antiplatelet Therapy after PCI
Optimal Duration and Dose of Antiplatelet Therapy after PCI Donghoon Choi, MD, PhD Severance Cardiovascular Center Yonsei University College of Medicine Optimal Duration of Antiplatelet Therapy after PCI
More informationThe randomized study of efficiency and safety of antithrombotic therapy in
.. [ ] 18 150 160 mg/d 2 mg/d INR 2.0 3.0( 75 INR 1.6 2.5) 704 369 335 420 59.7% 63.3 9.9 19 2 24 2.7% 6.0% P =0.03 OR 0.44 95% CI 0.198 0.960 56% 62% 1.8% 4.6% P =0.04 OR 0.38 95% CI 0.147 0.977 52% 10.6%
More informationHemostasis and Blood Forming Organs
Hemostasis and Blood Forming Organs Subcommittee: Williams, Patricia B. (Chair) pbwillia@umich.edu McMillan, David dcmcmillan@unmc.edu Dobrydneva, Yuliya dobrydy@evms.edu DEFEROXAMINE FERROUS SULFATE ferrous
More informationNews Release. For UK Media
News Release For UK Media Bayer plc 400 South Oak Way Reading RG2 6AD www.bayer.co.uk Bayer s Xarelto (rivaroxaban) in combination with single antiplatelet therapy receives positive CHMP opinion for treatment
More informationNew Data Reaffirm Positive Benefit-Risk Balance of Bayer s Xarelto in Patients with Atrial Fibrillation in Daily Clinical Practice
Investor News Not intended for U.S. and UK Media Bayer AG Investor Relations 51368 Leverkusen Germany www.investor.bayer.com 12 th Annual Congress of the European Cardiac Arrhythmia Society (ECAS) 2016:
More informationAssessing Cardiac Risk in Noncardiac Surgery. Murali Sivarajan, M.D. Professor University of Washington Seattle, Washington
Assessing Cardiac Risk in Noncardiac Surgery Murali Sivarajan, M.D. Professor University of Washington Seattle, Washington Disclosure None. I have no conflicts of interest, financial or otherwise. CME
More informationOUTCOMES WITH LONGTERM DUAL ANTIPLATELET THERAPY AFTER CORONARY ANGIOPLASTY Ashok Kumar Arigonda, K. Nagendra Prasad, O. Hareesh, R.
INDIAN JOURNAL OF CARDIOVACULAR DIEAE JOURNAL in women (IJCD) 016 VOL 1 IUE 3 ORIGINAL ARTICLE 1 OUTCOME WITH LONGTERM DUAL ANTIPLATELET THERAPY AFTER CORONARY ANGIOPLATY Ashok Kumar Arigonda, K. Nagendra
More information2017 Bryan Health Primary Care Conference. Dale Hansen MD Bryan Heart 5/20/17
2017 Bryan Health Primary Care Conference Dale Hansen MD Bryan Heart 5/20/17 I have no financial disclosures or conflicts of interest Bridging Anticoagulation Primum Non Nocere 67 y.o. male with mechanical
More informationDual Antiplatelet Therapy Made Practical
Dual Antiplatelet Therapy Made Practical David Parra, Pharm.D., FCCP, BCPS Clinical Pharmacy Program Manager in Cardiology/Anticoagulation VISN 8 Pharmacy Benefits Management Clinical Associate Professor
More informationLong-Term Care Updates
Long-Term Care Updates October/November 2015 By Daniel Kerner, PharmD A stroke occurs when blood flow to the brain is stopped or slowed, resulting in death or damage to brain cells. There are three main
More informationPrasugrel vs. Ticagrelor in ACS/PCI Which one to choose? V. Voudris MD FESC FACC 2 nd Cardiology Division Onassis Cardiac Surgery Center
Prasugrel vs. Ticagrelor in ACS/PCI Which one to choose? V. Voudris MD FESC FACC 2 nd Cardiology Division Onassis Cardiac Surgery Center Hospitalizations in the U.S. Due to ACS Acute Coronary Syndromes
More informationNorth Wales Cardiac Network Guidelines on oral antiplatelet therapy in cardiovascular disease
Guidelines on oral antiplatelet therapy in cardiovascular disease This guidance should be considered as one part of the wider therapeutic management of patients. The indication for antiplatelet therapy
More informationFACTOR Xa AND PAR-1 BLOCKER : ATLAS-2, APPRAISE-2 & TRACER TRIALS
New Horizons In Atherothrombosis Treatment 2012 순환기춘계학술대회 FACTOR Xa AND PAR-1 BLOCKER : ATLAS-2, APPRAISE-2 & TRACER TRIALS Division of Cardiology, Jeonbuk National University Medical School Jei Keon Chae,
More informationBranko N Huisa M.D. Assistant Professor of Neurology UNM Stroke Center
Branko N Huisa M.D. Assistant Professor of Neurology UNM Stroke Center THE END! CHANGABLE Blood pressure Diabetes Mellitus Hyperlipidemia Atrial fibrillation Nicotine Drug abuse Life style NOT CHANGABLE
More informationPIONEER AF-PCI Study with Bayer s Xarelto Accepted as Late- Breaking Clinical Trial Presentation at AHA 2016
News Release Not intended for U.S. and UK Media Bayer AG Communications, Government Relations & Corporate Brand 51368 Leverkusen Germany Tel. +49 214 30-0 www.news.bayer.com American Heart Association
More informationAntiplatelet Therapy in Primary CVD Prevention and Stable Coronary Artery Disease. Καρακώστας Γεώργιος Διευθυντής Καρδιολογικής Κλινικής, Γ.Ν.
Antiplatelet Therapy in Primary CVD Prevention and Stable Coronary Artery Disease Καρακώστας Γεώργιος Διευθυντής Καρδιολογικής Κλινικής, Γ.Ν.Κιλκίς Primary CVD Prevention A co-ordinated set of actions,
More information03/30/2016 DISCLOSURES TO OPERATE OR NOT THAT IS THE QUESTION CAROTID INTERVENTION IS INDICATED FOR ASYMPTOMATIC CAROTID OCCLUSIVE DISEASE
CAROTID INTERVENTION IS INDICATED FOR ASYMPTOMATIC CAROTID OCCLUSIVE DISEASE Elizabeth L. Detschelt, M.D. Allegheny Health Network Vascular and Endovascular Symposium April 2, 2016 DISCLOSURES I have no
More informationOccurrence of Bleeding and Thrombosis during Antiplatelet therapy In Non-cardiac surgery. A prospective observational study.
Occurrence of Bleeding and Thrombosis during Antiplatelet therapy In Non-cardiac surgery A prospective observational study OBTAIN Study Statistical Analysis Plan of Final Analysis Final Version: V1.1 from
More informationTitle of Guideline (must include the word Guideline (not protocol, policy, procedure etc) Contact Name and Job Title (author)
Title of Guideline (must include the word Guideline (not protocol, policy, procedure etc) Contact Name and Job Title (author) Guideline for Patients on antiplatelet agents undergoing Elective, Non-cardiac
More informationPRASUGREL HYDROCHLORIDE (Effient Eli Lilly Canada Inc.) Indication: Acute Coronary Syndrome
CEDAC FINAL RECOMMENDATION PRASUGREL HYDROCHLORIDE (Effient Eli Lilly Canada Inc.) Indication: Acute Coronary Syndrome Recommendation: The Canadian Expert Drug Advisory Committee (CEDAC) recommends that
More informationSafety of Arthrocentesis and Joint Injection in Patients Receiving Anticoagulation at Therapeutic Levels
CLINICAL RESEARCH STUDY Safety of Arthrocentesis and Joint Injection in Patients Receiving Anticoagulation at Therapeutic Levels Imdad Ahmed, MBBS, a,b Elie Gertner, MD a,b a Department of Internal Medicine,
More informationRisks and Benefits of Anticoagulant and Antiplatelet Medication Use before Cataract Surgery
Risks and Benefits of Anticoagulant and Antiplatelet Medication Use before Cataract Surgery Joanne Katz, ScD, 1,2 Marc A. Feldman, MD, MPH, 3 Eric B. Bass, MD, MPH, 4 Lisa H. Lubomski, PhD, 2 James M.
More informationAntiplatelets in cardiac patients with suspected GI bleeding
Antiplatelets in cardiac patients with suspected GI bleeding Acute GI bleeding is a common major medical emergency. In the 2007 UK-wide audit, overall mortality of patients admitted with acute GI bleeding
More informationAn Audit of the Post-Operative Management of Patients taking Warfarin
An Audit of the Post-Operative Management of Patients taking Warfarin Helen Wrightson Pre-Registration Pharmacist, Salisbury District Hospital March 2014 An Audit of the Post-Operative Management of Patients
More informationWhat oral antiplatelet therapy would you choose? a) ASA alone b) ASA + Clopidogrel c) ASA + Prasugrel d) ASA + Ticagrelor
76 year old female Prior Hypertension, Hyperlipidemia, Smoking On Hydrochlorothiazide, Atorvastatin New onset chest discomfort; 2 episodes in past 24 hours Heart rate 122/min; BP 170/92 mm Hg, Killip Class
More informationAre There Any Special Instructions When Taking Warfarin
Are There Any Special Instructions When Taking Warfarin Prescriptions drugs of concern when taking warfarin include: Follow the instructions of your health care provider and read carefully all product
More informationAntithrombotic. DAPT or OAC?
Antithrombotic treatment after TAVI: DAPT or OAC? Striking the right balance. Pascal Vranckx MD, PhD. Hartcentrum Hasselt, Belgium. Disclosure of Interest Pascal Vranckx has the following potential conflicts
More informationSafety of Outpatient Dalteparin Therapy in Veterans with Mechanical Heart Valves
Safety of Outpatient Dalteparin Therapy in Veterans with Mechanical Heart Valves Jessica L. O Neill, Pharm.D., Petra S. Flanagan, Pharm.D., Carolyn R. Zaleon, Pharm.D., and Laurel A. Copeland, Ph.D. Study
More informationGestione peri-operatoria del paziente in terapia con antagonisti della vitamina K. B. Cosmi
Gestione peri-operatoria del paziente in terapia con antagonisti della vitamina K B. Cosmi Department of Angiology and Blood Coagulation S. Orsola-Malpighi University Hospital Bologna, Italy Overview Background
More information5/2/2016. Outpatient Stroke Management Sheila Smith MD May 5, 2016
Outpatient Stroke Management Sheila Smith MD May 5, 2016 1 Management of Outpatient Stroke Objectives Review blood pressure management post stroke Review antithrombotic therapy Review statin therapy Discuss
More informationAntithrombotic therapy in CAD patients with concomitant NAFV: why and for whom?
Antithrombotic therapy in CAD patients with concomitant NAFV: why and for whom? Institut de Cardiologie de la Pitié-Salpêtrière jean-philippe.collet@psl.aphp.fr www.action-coeur.org Patients (%) Patients
More informationt. Recommendations for periprocedural anticoagulation are available lhrough the American College of Chest Physicians Clinical Practice Guidelines.
Name or Policy: Policy Number: 3364-133-116 Department: Approving Officer: Responsible Agent: cope: x Management of Anticoagulation with Invasive Procedures Pharmacy Chief Operating Officer Director of
More information